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Low dose methotrexate and vinblastine, given weekly to patients
with desmoid tumours, is associated with major toxicity
RENE ´ L. VAN DER HUL
1, CAROLINE SEYNAEVE
2,
BERT N. VAN GEEL
1 & JAAP VERWEIJ
2
Departments of
1Surgical Oncology and
2Medical Oncology, Erasmus Medical Center – Daniel den Hoed,
Rotterdam, The Netherlands
Abstract
Purpose: To evaluate the tolerance of a low dose chemotherapy regimen for desmoid tumours.
Patients and methods: Patients with desmoids for whom radical resection was impossible or related to extensive mutilation
were treated with chemotherapy. Treatment consisted of intravenous methotrexate at a dose of 50mg and vinblastine at a
dose of 10mg weekly, scheduled to be given for a total period of 1 year. Doses were reduced and/or delayed on an individual
basis, depending on the observed type of toxicity.
Results: Ten patients (six males; four females), median age 43 years (range17–75), median WHO performance score 1
(range 0–1), were treated. None of them was able to complete the treatment as scheduled, due to observed side effects,
while in two patients treatment was also discontinued because of progressive disease. In six patients, less than 50% of the
projected administrations and dose could be given. Severe organ toxicity was noted in three patients (one interstitial
pneumonitis, two toxic hepatitis), which, however, was reversible in all cases.
Discussion: Methotrexate and vinblastine given at this dose and schedule lead to an unacceptable level of toxicity for a
long-term treatment, and cannot be recommended for standard use.
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Introduction
Desmoid tumours arise from musculoaponeurotic
tissues and aggressively infiltrate along fascial planes.
Although they do not metastasise, they may cause
great local problems which can eventually become
lethal or require mutilating surgery. Because palp-
able lesions are often the ‘tip of the iceberg’ and
because it is difficult to distinguish a clear margin of
these tumours on CT or MRI-scan,
1 radical surgery
is frequently difficult. Moreover, tumours often
recur after surgical excision: even if microscopic
margins were clear on pathological examination,
local control rates average 72%.
2 Furthermore, and
as stated, in pursuing radical surgery important
mutilation can be inflicted upon the patient. In view
of this, tumour mass reduction by treatment other
than surgery is appealing. Weiss and Lackman
reported a low-dose chemotherapy regimen invol-
ving weekly administration of methotrexate (MTX),
at a dose of 50mg and vinblastine (VBL), at a dose
of 10mg, or MTX 50mg weekly with oral etoposide
50mg daily, all for a total treatment duration of 1
year.
3,4 They reported a long-lasting complete or
partial remission in 28 of their 36 patients, while
only seven patients experienced a transient poly-
neuropathy as adverse event. Based on these results
we routinely applied the above-mentioned regimen
of MTX and VBL in patients presenting with
primary or recurrent desmoid tumours at sites
requiring mutilating surgery. Since we encountered
side effects that seem more severe than previously
reported, we analysed our data and report on our
experience.
Patients and methods
Patients were eligible for chemotherapy if they met
the following criteria: age>18 years, performance
score 0–1 (WHO), histologically proven primary or
recurrent desmoid tumour requiring mutilating
surgery, white blood cell count>4.0 10
9/l, platelets
>100 10
9/l, normal serum creatinine and serum
bilirubin, no sign of peripheral neuropathy.
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MTX at a dose of 50mg and VBL at a dose of 10mg,
both given as a short intravenous bolus infusion.
Dose modifications were individualized, depending
on the observed side effects. In case of nausea and/or
vomiting intravenous administration of 8mg ondan-
setron was prophylactically applied on day 1 and oral
metoclopramide was prescribed at a daily dose of
20–60mg. The administration of chemotherapy was
scheduled to be given for a total of 52 weeks. Prior to
treatment a medical history was taken and physical
examination was performed. Full blood counts and
serum chemistry (creatinine, sodium, potassium,
bilirubine, alkaline phosphatase, AST, ALT, and
total protein) were assessed. During treatment,
blood counts were taken weekly, biochemistry was
assessed every 4 weeks.
Toxicity was assessed weekly and graded accord-
ing to NCI-CTC criteria, version 2.0. Response was
assessed by repeated tumour assessment (usually
by means of CT-scan) every 8–12 weeks. WHO
response criteria were used.
Results
Between 01-09-1996 and 31-12-2001, 10 patients
with primary or recurrent symptomatic desmoid
tumours were treated with chemotherapy. Patient
characteristics are shown in Table 1. Four patients
had previously undergone surgical resection. Two of
them had received multiple treatments: one patient
was treated with an isolated limb perfusion with
tumour necrosis factor and melphalan after the first
resection, followed by re-resection; another patient
was treated with radiotherapy after the first resection,
followed by re-resection.
Median follow-up was 30 months (10–78
months). The recorded side effects and their con-
sequences are depicted in Table 2. Of note, all
patients experienced nausea varying from grade I to
III despite anti-emetics. Nausea mainly occurred
on days 2 and 3 after the intravenous drug
administration. Four patients developed polyneuro-
pathy (grade I–III), four had continuous fatigue
(grade I–II), two developed leucopenia (grade II–III)
and two patients developed grade II–III impairment
of liver functions. The most severe side effect was
seen in patient B, who developed dyspnoea grade III
during the course of his treatment: a chest X-ray
revealed bilateral diffuse interstitial infiltration com-
patible with MTX-induced interstitial pneumonitis.
This diagnosis was histologically confirmed by tissue
obtained by open lung biopsy. After termination of
the treatment and addition of corticosteroids, the
signs and symptoms resolved within a few weeks.
Figure 1 shows the course of the treatment in each
patient and their final cumulative dose of MTX and
VBL as a percentage of the projected cumulative
dose (after 52 administrations). Of note, no patient
was able to receive the projected treatment. Six of 10
received less than 50% of the projected cumulative
dose, three patients received between 50 and 90% of
the dose, while one patient is still on treatment.
One patient achieved a complete remission lasting
21 weeks, seven patients had stable disease. Two of
the seven patients with stable disease experienced
symptom improvement. Two patients progressed
despite their treatment.
Discussion
In this report we describe an unexpected high level
of adverse events in a low dose regimen of MTX
and VBL given weekly to patients with desmoids that
can only be removed by mutilating surgery. Our
experience sharply contrasts with previous reports.
While Weiss and Lackman
3,4 reported good
tolerance and good activity of this regimen, our
results suggest poor tolerance and modest activity.
However, as far as activity is concerned we have to be
cautious. Our series is much smaller than the one
reported by Weiss, and confidence limits for the
Table 1. Patient characteristics
Patient Gender
Age
(years)
Tumour
site
Primary/
recurrent Prior treatment
WHO
performance score
A m 24 Lower abdominal
wall/groin
Primary – 0
B m 36 Shoulder girdle Primary – 0
C m 45 Sole of foot Second Recurrence Resection, ILP
and reresection
1
D m 55 Infraclavicular thorax Recurrent Resection 1
E m 58 Posterior to clavicle Primary – 1
F m 75 Thoracic wall/axilla Primary – 1
G F 17 Sole of foot Recurrent Resection 1
H F 31 Flexor compartment
upper leg
Second Recurrence Resection,
RT and reresection
1
I F 40 Retro peritoneal Primary – 0
J F 44 Lower pelvis Primary – 1
Abbreviations: m, male; f, female; ILP, isolated limb perfusion; RT, radiotherapy.
154 R.L. van der Hul et al.Table 2. Side effects (worst grade) and treatment consequences
Patient Nausea PNP Fatigue Leucopenia
Impaired LF
(AST/ALT) Other
Comment on
chemotherapy
A gr II (10) gr III (21) Treatment delay for MTX (10);
subsequent dose reduction for
MTX (18); treatment
discontinuation (21) all because
of impaired LF
B gr I (3) gr I (3) Dyspnoea gr III
MTX-pneumonitis (22)
Treatment discontinuation (22)
because of MTX-pneumonitis
C gr II (3) Headache gr I (3) 50% dose reduction for VBL (3)
because of persisting nausea;
treatment completion after 1 year
D gr I (12) Diarrhoea gr I (12) Treatment discontinued (18)
because of PD
E gr II (4) gr III * gr II (7) Alopecea gr I (4) 50% dose reduction for VBL (7)
and finally treatment discontinuation
because of persisting nausea,
fatigue and PNP*
F gr II (15) gr I (5) gr III (36) Skipping every third dose of VBL (5)
and treatment discontinuation (39)
because of leucopenia
G gr II (38) gr I (12) Treatment completed after 1 year;
delay because of patient compliance
H gr III (3) gr I (3) gr II (3) Vomitus gr III (3) Treatment discontinued (3) because
of persisting nausea, vomitus and
impaired LF
I gr I (7) gr I (7) gr I (7) Diarrhoea gr II (2);
Vomitus gr I (7)
50% dose reduction for VBL (6);
deletion of VBL (22) because
of diarrhoea and vomitus
J gr II (2) gr II (2) Vomitus gr II (14) 30% dose reduction for MTX;
dose interval increase to 10 days (9);
treatment discontinuation (14)
because of leucopenia and nausea.
Also PD
Abbreviations: PNP, polyneuropathy; LF, liver function; gr, grade of toxicity according to NCI-CTC criteria; PD, progressive disease.
Between parentheses, the number of gifts at which the side effects of worst severity first occurred.
*One-sided neuropathy of the hand, progressively worsening, in a patient with a history of diabetes mellitus and carpal tunnel syndrome.
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5observations are thus large. In addition, it is difficult
to assess potential differences in patient selection.
We simply may have selected patients with disease
characteristics that are less favourable for response
to chemotherapy. More of concern is the observed
level of toxicity, including severe organ toxicity.
The occurrence of a MTX-induced interstitial
pneumonitis is rare but well documented.
5
Furthermore, the drug is known to induce hepato-
toxicity and we had to stop treatment in two patients
due to a progressive relatively severe grade of
transaminitis. Fortunately this side effect was rever-
sible. Of further concern is the level of neurotoxicity
that we observed. Recently Weiss et al.
6 have
suggested to replace VBL by vinorelbine, a drug
that induces less neurotoxicity but is not devoid of
this side effect. Obviously a schedule of MTX and
vinorelbine would still bear the risk of MTX toxicity.
Due to the high incidence of various degrees of
toxicity, we were unable to administer the projected
drug administrations and doses in all patients.
Importantly, in six of them it is already evident that
we could administer less than 50% of dose and
administrations. These findings are in accordance
with the results of Azzarelli et al.:
7 they undertook a
phase II study and treated 30 patients with the same
regimen and were only able to treat one patient for a
full year and the median dose interval was 10 days.
In 15 patients (50%), it was decided to discontinue
treatment within 6 months. Four of them received
fewerthan15cycles ofchemotherapy,mainlybecause
of severe myelotoxicity. It was acknowledged that the
treatment was toxic but that it was useful and that
there seemed to be an advantage to attempting
to treat beyond 20 weeks, if possible. However, in
our series, treatment was delayed or discontinued
because of other reasons than myelotoxicity in eight
of 10 patients. We think that already in a phase I
protocol design such a low level of tolerance would
lead to the conclusion that the scheduled dose
exceeds the maximum tolerable dose. In any regimen
with frequent low dosing, issues such as long-term
tolerance and achieved long-term dose intensity
should be taken into account. Based on our results,
we cannot recommend this dose and schedule of
MTX and VBL for routine use.
Desmoids are relatively rare tumours, which is
reflected by the low number of publications involving
substantial sample sizes. Beyond any doubt, radical
resection with clear margins is still the mainstay of
treatment.
8 The additive value of radiotherapy to
achieve local control has been suggested
2 but, due to
the limited size of prospective studies performed, the
role of radiotherapy cannot yet be determined with
full certainty. This calls for prospective studies on the
relevance of treatment interventions and such studies
can likely only be performed in cooperative group
settings or even intergroup collaborations. Recently
the EORTC Soft Tissue and Bone Sarcoma Group
initiated a radiotherapy study. The objective of this
study will be to determine the efficacy of moderate
doses of radiotherapy for desmoid tumours and it
will indicate if prospective studies are feasible within
a limited time frame.
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Fig. 1. Projected versus achieved drug administrations and total dose. Between parentheses, the final cumulative dose of MTX and
VB given to the patient as a percentage of the projected cumulative dose. *Patient I still on treatment.
156 R.L. van der Hul et al.In conclusion, MTX and VBL at this dose
and schedule lead to unacceptable toxicity and
impossibility to complete treatment. Other regimens
will have to be developed. Performance of prospective
trials in cooperative group setting is recommended.
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